1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Nicastro, G.
Franzoni, L.
De Chiara, C.
Mancin, C.A.
Giglio, J.R.
Spisni, A.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
IX
Eur.J.Biochem.
EJBCAI
0262
0014-2956
270
1969
10.1046/J.1432-1033.2003.03563.X
12709056
Solution Structure of Crotamine, a Na+ Channel Affecting Toxin from Crotalus Durissus Terrificus Venom
2003
UK
Toxicon
TOXIA6
2043
0041-0101
36
1927
10.1016/S0041-0101(98)00117-2
9839677
The Analgesic Activity of Crotamine,A Neurotoxin from Crotalus Durissus Terrificus Venom:A Biochemical and Pharmacological Study
1998
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
4902.878
MYOTOXIN
1
nat
polymer
CROTAMINE
no
no
YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG
YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
SOUTH AMERICAN RATTLESNAKE
VENOM OF THE RATTLESNAKE CROTALUS DURISSUS TERRIFICUS
sample
8732
CROTALUS DURISSUS TERRIFICUS
repository
Initial release
Derived calculations
Other
Structure summary
Version format compliance
1
0
2003-05-09
1
1
2013-07-24
HELIX
DETERMINATION METHOD: AUTHOR PROVIDED.
SHEET
DETERMINATION METHOD: AUTHOR PROVIDED.
PDBE
Y
PDBE
2001-05-23
REL
EXTREMELY RAPID ACTING TOXIN THAT CAUSES MUSCLE NECROSIS.
DISABLES PREY BY CAUSING INSTANTANEOUS PARALYSIS OF HIND
LIMBS AND DEATH BY PARALYSIS OF THE DIAPHRAGM.
THE STRUCTURE WAS DETERMINED USING HOMONUCLEAR 1H-1H 2D NMR ON THE NATURAL TOXIN EXTRACTED FROM THE SNAKE VENOM.
LEAST RESTRAINT VIOLATION, LEAST RESIDUAL DEVIATIONS FROM IDEALIZED GEOMETRY
50
26
TOCSY
NOESY
DQF-COSY
4.0
pH
308
K
SEE JRNL CITATION
simulated annealing
1MM CROTAMINE, H2O/TFE (70/30)
BIOSYM
refinement
DISCOVER
structure solution
MSI DISCOVER
DISCOVER
600
Bruker
DMX
800
Bruker
DMX
TYR
1
n
1
TYR
1
A
LYS
2
n
2
LYS
2
A
GLN
3
n
3
GLN
3
A
CYS
4
n
4
CYS
4
A
HIS
5
n
5
HIS
5
A
LYS
6
n
6
LYS
6
A
LYS
7
n
7
LYS
7
A
GLY
8
n
8
GLY
8
A
GLY
9
n
9
GLY
9
A
HIS
10
n
10
HIS
10
A
CYS
11
n
11
CYS
11
A
PHE
12
n
12
PHE
12
A
PRO
13
n
13
PRO
13
A
LYS
14
n
14
LYS
14
A
GLU
15
n
15
GLU
15
A
LYS
16
n
16
LYS
16
A
ILE
17
n
17
ILE
17
A
CYS
18
n
18
CYS
18
A
LEU
19
n
19
LEU
19
A
PRO
20
n
20
PRO
20
A
PRO
21
n
21
PRO
21
A
SER
22
n
22
SER
22
A
SER
23
n
23
SER
23
A
ASP
24
n
24
ASP
24
A
PHE
25
n
25
PHE
25
A
GLY
26
n
26
GLY
26
A
LYS
27
n
27
LYS
27
A
MET
28
n
28
MET
28
A
ASP
29
n
29
ASP
29
A
CYS
30
n
30
CYS
30
A
ARG
31
n
31
ARG
31
A
TRP
32
n
32
TRP
32
A
ARG
33
n
33
ARG
33
A
TRP
34
n
34
TRP
34
A
LYS
35
n
35
LYS
35
A
CYS
36
n
36
CYS
36
A
CYS
37
n
37
CYS
37
A
LYS
38
n
38
LYS
38
A
LYS
39
n
39
LYS
39
A
GLY
40
n
40
GLY
40
A
SER
41
n
41
SER
41
A
GLY
42
n
42
GLY
42
A
software_defined_assembly
PISA
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
O
PHE
12
A
O
PHE
12
A
N
LYS
35
A
N
LYS
35
A
O
PHE
25
A
O
PHE
25
A
N
CYS
36
A
N
CYS
36
1
A
A
H1
OD2
TYR
ASP
1
29
1.53
2
A
A
H1
OD1
TYR
ASP
1
29
1.54
2
A
A
OD1
HZ3
ASP
LYS
24
35
1.58
3
A
A
H3
OD2
TYR
ASP
1
29
1.56
5
A
A
OD2
HZ3
ASP
LYS
24
35
1.58
5
A
A
O
HG
SER
SER
22
23
1.59
5
A
A
H2
OD2
TYR
ASP
1
29
1.60
6
A
A
H2
OD2
TYR
ASP
1
29
1.53
6
A
A
OE1
HH21
GLU
ARG
15
33
1.59
9
A
A
H2
OD2
TYR
ASP
1
29
1.53
10
A
A
O
HG
SER
SER
22
23
1.56
12
A
A
H1
OD2
TYR
ASP
1
29
1.56
13
A
A
H2
OD2
TYR
ASP
1
29
1.59
14
A
A
H1
OD2
TYR
ASP
1
29
1.56
15
A
A
HG
O
SER
GLY
23
42
1.45
16
A
A
H2
OD2
TYR
ASP
1
29
1.55
17
A
A
H1
OD2
TYR
ASP
1
29
1.59
18
A
A
HZ2
O
LYS
GLY
39
42
1.59
21
A
A
H1
OD2
TYR
ASP
1
29
1.58
22
A
A
OD1
HZ2
ASP
LYS
24
35
1.54
22
A
A
HG
O
SER
LYS
22
39
1.58
23
A
A
H3
OD2
TYR
ASP
1
29
1.55
24
A
A
HZ2
O
LYS
GLY
38
42
1.55
26
A
A
H2
OD2
TYR
ASP
1
29
1.54
1
7.91
1.30
111.50
119.41
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
1
7.91
1.30
111.50
119.41
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
2
7.91
1.30
111.50
119.41
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
2
7.83
1.30
111.50
119.33
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
3
7.86
1.30
111.50
119.36
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
3
7.88
1.30
111.50
119.38
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
4
7.86
1.30
111.50
119.36
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
4
7.96
1.30
111.50
119.46
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
4
-5.41
0.90
109.00
103.59
A
A
A
CD1
NE1
CE2
TRP
TRP
TRP
32
32
32
N
5
7.93
1.30
111.50
119.43
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
6
7.92
1.30
111.50
119.42
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
6
7.81
1.30
111.50
119.31
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
7
7.89
1.30
111.50
119.39
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
7
7.87
1.30
111.50
119.37
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
7
-5.40
0.90
109.00
103.60
A
A
A
CD1
NE1
CE2
TRP
TRP
TRP
32
32
32
N
8
7.90
1.30
111.50
119.40
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
8
7.90
1.30
111.50
119.40
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
9
7.96
1.30
111.50
119.46
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
9
7.84
1.30
111.50
119.34
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
10
7.91
1.30
111.50
119.41
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
10
7.86
1.30
111.50
119.36
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
11
7.92
1.30
111.50
119.42
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
11
7.86
1.30
111.50
119.36
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
12
7.92
1.30
111.50
119.42
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
12
7.85
1.30
111.50
119.35
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
13
7.93
1.30
111.50
119.43
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
13
7.87
1.30
111.50
119.37
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
14
7.95
1.30
111.50
119.45
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
14
7.89
1.30
111.50
119.39
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
15
7.96
1.30
111.50
119.46
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
15
7.87
1.30
111.50
119.37
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
16
7.92
1.30
111.50
119.42
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
16
7.94
1.30
111.50
119.44
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
16
-5.47
0.90
109.00
103.53
A
A
A
CD1
NE1
CE2
TRP
TRP
TRP
32
32
32
N
17
7.93
1.30
111.50
119.43
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
17
7.95
1.30
111.50
119.45
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
18
7.93
1.30
111.50
119.43
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
18
7.90
1.30
111.50
119.40
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
19
7.90
1.30
111.50
119.40
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
19
7.96
1.30
111.50
119.46
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
20
7.95
1.30
111.50
119.45
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
20
7.88
1.30
111.50
119.38
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
20
-5.41
0.90
109.00
103.59
A
A
A
CD1
NE1
CE2
TRP
TRP
TRP
32
32
32
N
21
7.94
1.30
111.50
119.44
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
21
7.91
1.30
111.50
119.41
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
22
7.91
1.30
111.50
119.41
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
22
7.91
1.30
111.50
119.41
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
23
7.98
1.30
111.50
119.48
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
23
7.87
1.30
111.50
119.37
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
24
7.92
1.30
111.50
119.42
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
24
7.95
1.30
111.50
119.45
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
25
7.93
1.30
111.50
119.43
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
25
7.90
1.30
111.50
119.40
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
25
-5.45
0.90
109.00
103.55
A
A
A
CD1
NE1
CE2
TRP
TRP
TRP
32
32
32
N
26
7.99
1.30
111.50
119.49
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
5
5
5
N
26
7.95
1.30
111.50
119.45
A
A
A
ND1
CE1
NE2
HIS
HIS
HIS
10
10
10
N
1
A
SER
23
-162.53
98.27
1
A
LYS
39
-145.96
-63.54
2
A
SER
23
-163.74
74.64
2
A
MET
28
-98.48
-74.52
2
A
CYS
30
-129.97
-103.00
2
A
SER
41
-161.61
-51.25
3
A
LYS
2
-173.81
-71.92
3
A
SER
22
-92.58
56.73
3
A
MET
28
-82.17
-111.02
4
A
PRO
13
-58.05
173.49
4
A
SER
22
-93.45
52.62
4
A
SER
23
-150.23
77.88
4
A
MET
28
-84.50
-76.26
4
A
CYS
30
-114.10
-157.78
4
A
LYS
39
-94.28
-68.98
5
A
SER
22
-90.50
58.91
5
A
SER
23
-162.48
83.20
5
A
MET
28
-90.19
-113.63
5
A
ASP
29
-110.62
68.64
5
A
CYS
30
-142.26
-88.68
5
A
LYS
39
-152.11
-145.36
6
A
LYS
2
-87.19
-78.26
6
A
ASP
29
-151.72
57.65
6
A
CYS
30
-123.32
-105.36
6
A
SER
41
-75.52
-87.62
7
A
SER
22
-90.06
59.43
7
A
SER
23
-161.27
85.75
7
A
MET
28
-89.50
-77.52
7
A
ASP
29
-145.86
43.85
7
A
CYS
30
-134.11
-151.21
8
A
LYS
2
-132.32
-69.84
8
A
SER
22
-96.93
50.46
8
A
SER
23
-152.11
78.53
8
A
MET
28
-89.34
-121.40
8
A
ASP
29
-95.54
48.51
8
A
CYS
30
-131.53
-93.39
9
A
LYS
2
-90.44
-80.32
9
A
SER
22
-85.60
48.90
9
A
SER
23
-167.81
72.51
9
A
MET
28
-86.01
-86.37
9
A
ASP
29
-140.72
50.60
9
A
CYS
30
-98.98
-90.92
9
A
LYS
39
-113.60
-162.10
10
A
LYS
2
-95.17
-71.73
10
A
SER
23
-165.99
71.01
10
A
MET
28
-117.98
-95.39
10
A
CYS
30
-144.85
-77.80
10
A
SER
41
-152.68
79.25
11
A
LYS
2
-91.65
-72.29
11
A
SER
23
-100.42
50.02
11
A
MET
28
-71.18
-79.61
11
A
ASP
29
-111.05
52.95
11
A
ARG
31
-79.96
-165.78
12
A
MET
28
-84.88
-108.66
12
A
ASP
29
-108.23
66.80
12
A
LYS
39
-99.32
-72.58
12
A
SER
41
60.73
61.26
13
A
LYS
2
-82.87
-86.71
13
A
MET
28
-117.91
-93.18
13
A
CYS
30
-123.28
-88.93
13
A
LYS
39
-135.69
-56.07
14
A
SER
22
-87.62
49.44
14
A
SER
23
-150.91
51.40
14
A
MET
28
-96.92
-118.81
15
A
LYS
2
-156.07
-58.15
15
A
PRO
21
-93.90
48.52
15
A
MET
28
-108.36
-116.01
15
A
ASP
29
-91.11
53.51
15
A
SER
41
-91.14
53.33
16
A
LYS
2
-99.41
-62.10
16
A
MET
28
-122.44
-106.30
16
A
ASP
29
-95.40
50.67
16
A
CYS
30
-157.47
-89.20
16
A
LYS
39
-154.86
-50.68
17
A
GLU
15
-150.19
-27.74
17
A
SER
23
-94.61
47.40
17
A
MET
28
-93.04
-112.01
17
A
CYS
30
-111.35
-83.24
17
A
LYS
38
-104.55
74.88
18
A
LYS
16
-90.25
-106.49
18
A
MET
28
-90.20
-81.24
18
A
ASP
29
-148.06
57.84
18
A
CYS
30
-135.13
-102.15
19
A
SER
22
-102.80
45.27
19
A
SER
23
-160.55
63.73
19
A
MET
28
-78.72
-85.28
19
A
SER
41
-163.77
72.96
20
A
LYS
2
-95.01
-66.41
20
A
SER
22
-92.98
58.69
20
A
SER
23
-164.20
88.19
20
A
MET
28
-107.45
-121.10
20
A
ASP
29
-100.24
66.05
20
A
CYS
30
-146.55
-142.25
20
A
LYS
39
-130.81
-71.51
20
A
SER
41
66.23
88.71
21
A
LYS
2
-90.47
-66.01
21
A
PRO
21
-93.19
52.27
21
A
MET
28
-95.58
-76.36
21
A
ASP
29
-153.41
58.74
21
A
CYS
30
-141.45
-71.23
21
A
LYS
39
-74.98
-135.55
22
A
LYS
2
-174.27
-69.76
22
A
PRO
21
-94.58
55.63
22
A
MET
28
-95.34
-115.97
23
A
LYS
2
-135.16
-70.16
23
A
SER
23
-162.44
80.73
23
A
MET
28
-86.98
-108.65
23
A
ASP
29
-103.53
50.61
24
A
LYS
2
-142.21
-137.68
24
A
GLU
15
-154.23
-35.84
24
A
MET
28
-83.37
-71.52
24
A
SER
41
-153.77
65.14
25
A
LYS
2
-107.97
-64.12
25
A
LYS
14
-85.12
45.90
25
A
GLU
15
-145.41
-29.02
25
A
SER
22
-94.70
59.26
25
A
SER
23
-166.18
69.16
25
A
MET
28
-119.42
-95.95
25
A
ASP
29
-107.79
53.71
26
A
LYS
2
-88.49
-71.65
26
A
GLU
15
-169.29
-32.20
26
A
SER
22
-140.05
-66.35
26
A
MET
28
-99.43
-120.39
26
A
ASP
29
-103.62
40.77
26
A
SER
41
-151.16
88.91
MYOTOXIN
Solution structure of Crotamine, a neurotoxin from Crotalus durissus terrificus
1
N
N
A
GLN
3
A
GLN
3
HELX_P
A
LYS
7
A
LYS
7
1
1
5
disulf
2.003
A
CYS
4
A
SG
CYS
4
1_555
A
CYS
36
A
SG
CYS
36
1_555
disulf
1.996
A
CYS
11
A
SG
CYS
11
1_555
A
CYS
30
A
SG
CYS
30
1_555
disulf
2.748
A
CYS
11
A
SG
CYS
11
1_555
A
CYS
36
A
SG
CYS
36
1_555
disulf
1.999
A
CYS
18
A
SG
CYS
18
1_555
A
CYS
37
A
SG
CYS
37
1_555
TOXIN
TOXIN, SODIUM CHANNEL AFFECTING TOXIN, VENOM
A
LEU
19
A
LEU
19
1
A
PRO
20
A
PRO
20
7.69
A
LEU
19
A
LEU
19
2
A
PRO
20
A
PRO
20
0.73
A
LEU
19
A
LEU
19
3
A
PRO
20
A
PRO
20
1.29
A
LEU
19
A
LEU
19
4
A
PRO
20
A
PRO
20
5.03
A
LEU
19
A
LEU
19
5
A
PRO
20
A
PRO
20
2.97
A
LEU
19
A
LEU
19
6
A
PRO
20
A
PRO
20
7.71
A
LEU
19
A
LEU
19
7
A
PRO
20
A
PRO
20
8.67
A
LEU
19
A
LEU
19
8
A
PRO
20
A
PRO
20
5.05
A
LEU
19
A
LEU
19
9
A
PRO
20
A
PRO
20
9.17
A
LEU
19
A
LEU
19
10
A
PRO
20
A
PRO
20
5.72
A
LEU
19
A
LEU
19
11
A
PRO
20
A
PRO
20
4.70
A
LEU
19
A
LEU
19
12
A
PRO
20
A
PRO
20
8.83
A
LEU
19
A
LEU
19
13
A
PRO
20
A
PRO
20
7.47
A
LEU
19
A
LEU
19
14
A
PRO
20
A
PRO
20
5.39
A
LEU
19
A
LEU
19
15
A
PRO
20
A
PRO
20
10.10
A
LEU
19
A
LEU
19
16
A
PRO
20
A
PRO
20
5.49
A
LEU
19
A
LEU
19
17
A
PRO
20
A
PRO
20
8.21
A
LEU
19
A
LEU
19
18
A
PRO
20
A
PRO
20
6.96
A
LEU
19
A
LEU
19
19
A
PRO
20
A
PRO
20
7.72
A
LEU
19
A
LEU
19
20
A
PRO
20
A
PRO
20
9.31
A
LEU
19
A
LEU
19
21
A
PRO
20
A
PRO
20
8.87
A
LEU
19
A
LEU
19
22
A
PRO
20
A
PRO
20
6.09
A
LEU
19
A
LEU
19
23
A
PRO
20
A
PRO
20
9.87
A
LEU
19
A
LEU
19
24
A
PRO
20
A
PRO
20
6.07
A
LEU
19
A
LEU
19
25
A
PRO
20
A
PRO
20
2.64
A
LEU
19
A
LEU
19
26
A
PRO
20
A
PRO
20
4.43
MYXC_CRODU
UNP
1
P01475
1
42
1H5O
1
42
P01475
A
1
1
42
3
anti-parallel
anti-parallel
A
GLY
9
A
GLY
9
A
PHE
12
A
PHE
12
A
LYS
35
A
LYS
35
A
LYS
38
A
LYS
38
A
ASP
24
A
ASP
24
A
PHE
25
A
PHE
25
1
P 1